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Abstract  
Zonisamide is an antiepileptic drug that acts on voltage-sensitive sodium and calcium 
channels, with modulatory effect on GABA-mediated neuronal inhibition and inhibitory 
effect on carbonic anhydrase. It is mainly used for the treatment of partial seizures, 
and is generally well tolerated at therapeutic doses. The most common reported 
adverse effects are somnolence, anorexia, dizziness, and headache. Zonisamide 
overdose data are limited in the literature and no case of zonisamide 
monointoxication has been published to date. We report the first case of zonisamide 
monointoxication in a 25-year-old female who ingested 12.6 g of this substance with 
suicidal intent. Despite a plasma zonisamide concentration of 182 mg/L at admission, 
the patient showed a benign clinical course with vomiting and CNS depression, 
requiring brief intubation. Somnolence persisted for 50 hours, normal-anion-gap 
metabolic acidosis and polyuria for several days. Complete recovery may be 
expected with supportive care, even after ingestion of large zonisamide overdoses. 
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1. Introduction 
Zonisamide (ZNS), a sulfonamide derivative, is an anti-epileptic drug (AED) that acts 
on voltage-sensitive sodium and T-type calcium channels [1,2], blocking potassium-
evoked glutamate response [3]. ZNS modulates GABA-mediated neuronal inhibition 
[4] and weakly inhibits carbonic anhydrase (CA) activity [5]. ZNS also affects 
dopaminergic and serotonergic neurotransmission [6]. For more than two decades, 
ZNS has been used as monotherapy and adjunctive therapy for the treatment of 
partial and generalized seizures in pediatric and adult patients in Japan [7]. ZNS was 
approved in the United States in 2000, and in Europe in 2005, for adjunctive 
treatment of partial seizures in adults. Additional evidence exists for ZNS as an 
effective monotherapy – off-label use – against complex partial seizures, generalized 
seizures and partial seizures secondarily generalized [8]. ZNS is also used off-label 
for other disorders such as chronic pain, Parkinson’s disease, restless legs 
syndrome, and migraine [8,9,10]. ZNS is generally safe and well tolerated at 
therapeutic doses. The most commonly reported adverse effects associated with 
ZNS use were somnolence, anorexia, dizziness, headache, nausea, and agitation–
irritation in a retrospective case study [11]. Although epileptic patients have a high 
incidence of psychiatric comorbidities with depression being the most common 
diagnosis [12], and AEDs are common agents taken in intentional drug overdose 
[13], limited data exist on overdose of ZNS, and to our knowledge no case of ZNS 
monointoxication has been published to date. There are two cases of ZNS poisoning 
reported in the literature, but in both, other AEDs in overdose were coingested 
[14,15].  
 
2. Case report 
A 25-year-old Caucasian woman with a history of simple and complex focal seizures, 
and secondarily generalized seizures since the age of 20 years, which were treated 
with 300 mg ZNS, 5 mg clobazam, and 150 mg lacosamide daily, was brought to the 
emergency department 8 hours after ingestion of 12.6 g of ZNS (126 x 100 mg-
tablets) with suicidal intent. The patient was also known to have a diagnosis of 
emotionally unstable personality disorder and depression, with earlier suicide 
attempts documented in her medical records. Her husband, who was permanently 
next to the patient before arrival at the hospital, observed vomiting and increasing 
somnolence, but no other symptoms. At admission, the patient was obtunded 
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(Glasgow Coma Scale score 9) and vomited repeatedly. Pulse rate was 87 beats/ 
min, blood pressure 103/54 mmHg, respiratory rate 20 breaths/min, and the body 
temperature was 35.8 °C. ECG showed mild QRS widening (102 ms) and QT 
prolongation (QTc 506 ms). Complete blood count revealed an elevation of white 
blood cells (17 x 109/L); all other values were within normal limits. The patient was 
intubated for airway protection, and a single dose of activated charcoal was 
administered by gastric tube. Arterial blood gas analysis (ABGA) after intubation 
showed a moderate lactic acidosis (pH 7.28, pCO2 5.19 kPa, pO2 20.1 kPa, 
bicarbonate 28.4 mmol/L, BE -7.3 mmol/L, lactate 5.5 mmol/L). Hemodialysis for 
enhanced elimination of ZNS [16] was not performed, because the patient’s vital 
signs remained stable. The patient’s level of consciousness improved within 8 hours 
from admission, and she was therefore extubated. She remained somnolent for 
another 50 hours, and transient generalized myoclonus and diplopia occurred. The 
following day (28 hours after admission), the ECG showed a normal QRS complex 
(90 ms) and the corrected QT interval decreased to 458 ms. The ECG was normal 
three days after admission (QRS 85 ms, QTc 398 ms). ABGA showed a normal-
anion-gap metabolic acidosis with partial respiratory compensation (pH 7.34, pCO2 
3.7 kPa, pO2 13.0 kPa, bicarbonate 17.0 mmol/L, BE -9.7 mmol/L, lactate 0.5 
mmol/L, chloride 117 mmol/L, sodium 136 mmol/L). This alteration gradually 
improved over the next 3 days, and there was no need for intravenous bicarbonate 
administration. Polyuria without alteration of other renal parameters was persistent at 
discharge (day 7).  
Laboratory analysis on admission (8 hours after ingestion of the AED) revealed a 
plasma ZNS concentration of 182 mg/L (therapeutic 10-40 mg/L [10]; high-
performance liquid chromatography). The markedly increased plasma ZNS 
concentration was confirmed in a second blood sample collected at the same time: 
202 mg/L. Moreover, therapeutic levels of clobazam (1.9 μmol/L; liquid 
chromatography-mass spectrometry) and lacosamide (4.4 μmol/L; high-performance 
liquid chromatography) were measured. A serum toxicological screening was positive 
for midazolam and ephedrin (both administered during intubation) and caffeine; no 
other substances were detected. Urine drug screening was positive for 
benzodiazepines, and negative for drugs of abuse. Plasma ZNS concentration 
repeated at discharge (day 7) was 1.8 mg/L. Therapeutic drug monitoring of ZNS one 
month before admission revealed a plasma concentration of 26.5 mg/L. 
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3. Discussion 
From previous studies it is known that ZNS is rapidly and completely absorbed after 
oral administration with peak plasma concentration achieved within 2-5 hours [17]. 
Following a 300 mg ZNS oral dose, a peak concentration of 3.48 mg/L can be 
expected [18]. In accordance with these data, plasma ZNS concentrations around 
180-200 mg/L were measured in our patient 8 hours after ingestion of 12.6 g ZNS. It 
has been shown that ZNS displays a linear pharmacokinetic in the therapeutic dose 
range [19]. There is some evidence that this may apply also to overdose conditions 
[14]. The plasma ZNS concentrations measured in our case on day 1 and day 7 are 
compatible with this elimination pattern. 
In the medical literature there are only two reported cases of ZNS overdose, but in 
both, also other AEDs were coingested in overdose, so that it is difficult to ascribe the 
reported symptoms and signs to a specific drug. For example, in one of these 
reports, a 26-year-old female developed coma, spontaneous horizontal nystagmus, 
myoclonus, bradycardia, hypotension and respiratory depression after ingesting an 
overdose (precise dose unknown) of ZNS and clonazepam. The high plasma 
concentrations of both ZNS (100.1 mg/L) and clonazepam (376 μg/L; therapeutic 
range 15-60 μg/L) measured 31 hours after the suicide attempt, suggest that the 
patient’s comatose state was probably due to a combined effect of both AEDs which 
were ingested in overdose. In this case, the estimated maximal plasma ZNS 
concentration by extrapolation was 143 mg/L [14]. 
In the other article, the clinical course of a 27-year-old woman who committed suicide 
with a mixed overdose of lacosamide (12 g), gabapentin (56 g), topiramate (2 g) and 
ZNS (2.8 g) is described. The patient was found comatose, and experienced 
repeated generalized seizures. Hypotension and an increase in the PR interval were 
documented. Blood concentrations of topiramate and ZNS were not measured until 
the day after admission, and were within normal limits (ZNS 18 mg/L, topiramate 3.7 
mg/L). Although lacosamide plasma concentration was not measured, most 
symptoms and signs were attributed to this drug [15]. 
Our patient showed symptoms and signs that are consistent with the adverse effects 
of ZNS observed in clinical trials, and which involved mainly the central nervous 
system, such as somnolence, anorexia, dizziness, ataxia, agitation/irritability and 
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vomiting as the most frequent, and more rarely nystagmus, diplopia and myoclonus. 
Beside CNS effects, our patient showed a normal-anion-gap acidosis and polyuria, 
which persisted significantly longer than the neurological effects. The metabolic 
acidosis presumably results from the inhibition of renal cortical CA, which is also 
reported in overdose with topiramate [20]. The inhibition of CA seems to play a minor 
role in the drug’s anticonvulsant activity, however ZNS seems to have an even more 
selective inhibitory effect than topiramate on CA isoform II and IV, both strongly 
expressed in the kidney [5]. However, the metabolic acidosis resulting from the ZNS-
mediated inhibition of renal cortical CA, seems to be of minimal clinical significance. 
Seizures were not observed during the 7-day hospitalisation period, although 
exacerbation of seizure activity has been described in association with overdose of 
several AEDs, also with the newer drugs [21]. Presumably the patient had sufficient 
seizure protection by her medication with clobazam and lacosamide. 
QRS widening and QT prolongation have not been previously described in ZNS 
overdose and deserve further confirmation, although widening of the QRS complex 
has been reported in poisoning with drugs that block voltage-sensitive sodium 
channels. For example, in a case of lamotrigine overdose, a QRS of 112 ms has 
been documented [22]. 
In conclusion, ZNS appears to be relatively safe in overdose. Due to the long serum 
half-life (50-70 h) of this drug [23], symptoms can persist for several days, but 
complete recovery can be expected with supportive care. 
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